Compare Fresenius Kabi Onco. with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DR. REDDYS LAB - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DR. REDDYS LAB FRESENIUS KABI ONCO./
DR. REDDYS LAB
 
P/E (TTM) x 22.1 40.2 55.1% View Chart
P/BV x 3.1 5.5 56.6% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   DR. REDDYS LAB
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DR. REDDYS LAB
Mar-20
FRESENIUS KABI ONCO./
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1763,363 5.2%   
Low Rs792,352 3.3%   
Sales per share (Unadj.) Rs37.71,054.2 3.6%  
Earnings per share (Unadj.) Rs5.1121.9 4.2%  
Cash flow per share (Unadj.) Rs6.7190.2 3.5%  
Dividends per share (Unadj.) Rs025.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs42.5938.7 4.5%  
Shares outstanding (eoy) m158.23166.17 95.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.7 124.6%   
Avg P/E ratio x25.023.4 106.6%  
P/CF ratio (eoy) x18.915.0 126.0%  
Price / Book Value ratio x3.03.0 98.3%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m20,135474,831 4.2%   
No. of employees `0001.221.7 5.3%   
Total wages/salary Rs m70333,802 2.1%   
Avg. sales/employee Rs Th5,176.28,091.0 64.0%   
Avg. wages/employee Rs Th610.41,561.3 39.1%   
Avg. net profit/employee Rs Th699.6935.8 74.8%   
INCOME DATA
Net Sales Rs m5,963175,170 3.4%  
Other income Rs m186,206 0.3%   
Total revenues Rs m5,981181,376 3.3%   
Gross profit Rs m1,43024,421 5.9%  
Depreciation Rs m25811,348 2.3%   
Interest Rs m-26983 -2.6%   
Profit before tax Rs m1,21618,296 6.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0561 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-1,403 -24.4%   
Profit after tax Rs m80620,260 4.0%  
Gross profit margin %24.013.9 172.0%  
Effective tax rate %28.1-7.7 -366.9%   
Net profit margin %13.511.6 116.9%  
BALANCE SHEET DATA
Current assets Rs m5,102125,991 4.0%   
Current liabilities Rs m2,38572,141 3.3%   
Net working cap to sales %45.630.7 148.2%  
Current ratio x2.11.7 122.5%  
Inventory Days Days15073 205.3%  
Debtors Days Days113105 108.1%  
Net fixed assets Rs m5,14883,854 6.1%   
Share capital Rs m158831 19.0%   
"Free" reserves Rs m6,556155,157 4.2%   
Net worth Rs m6,732155,988 4.3%   
Long term debt Rs m9521,304 73.0%   
Total assets Rs m10,388232,253 4.5%  
Interest coverage x-45.819.6 -233.4%   
Debt to equity ratio x0.10 1,692.0%  
Sales to assets ratio x0.60.8 76.1%   
Return on assets %7.59.1 82.1%  
Return on equity %12.013.0 92.2%  
Return on capital %14.612.6 115.8%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29884,193 6.3%   
Fx outflow Rs m1,77239,616 4.5%   
Net fx Rs m3,52544,577 7.9%   
CASH FLOW
From Operations Rs m1,27429,841 4.3%  
From Investments Rs m-1,204-4,923 24.5%  
From Financial Activity Rs m-196-25,159 0.8%  
Net Cashflow Rs m-126-266 47.5%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.4 5.6%  
FIIs % 9.6 35.3 27.2%  
ADR/GDR % 0.0 18.5 -  
Free float % 9.1 15.3 59.5%  
Shareholders   42,599 75,885 56.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   VENUS REMEDIES  SHASUN PHARMA  SANOFI INDIA  J.B.CHEMICALS  NEULAND LABS  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS